




Curriculum Vitae

1. Name, Gender, Nationality

Family Name	Name	Gender	Nationality
Curren	Rodger	Male	American



2. Overall Scientific Expertise

Expert Knowledge in:

Validation of Alternative Methods – Over 20 years of experience managing laboratories participating in national and international validation trials. Participation on validation management teams for many studies resulting in regulatory acceptance and OECD Test Guidelines. Co-authored over a dozen papers on the theory and/or practical application of validation concepts. Developed and published the concept of prevalidation.

In Vitro Test Systems – Thirty-five years of experience using and directing the use of in vitro test systems (human and rodent cells and tissues). Test areas included in vitro carcinogenesis, genetic toxicology, cellular functions, and efficacy studies.

Skin Irritation and Eye Irritation – Over 20 years of experience reviewing animal studies in these areas for the purpose of understanding the mechanistic relationship between the responses of the eye and skin to substances, and the responses of in vitro models to the same materials. Have overseen the conduct of thousands of in vitro eye and skin studies for industrial clients.

Genotoxicity and Mutagenicity – Fifteen years experience working in one of the world's largest commercial genetic toxicology facilities running multiple assay



systems under GLP conditions. Numerous publications in specific field of human cell mutagenesis.

3. Professional Experience

Professional Experience 1 (most recent)	
Occupation or position held	<i>President, Institute for In Vitro Sciences, Inc.</i>
Date (starting)	<i>15.03.1997</i>
Date (finishing)	<i>To Present</i>
Main activities	<i>Directs the scientific and business activities of a 20 employee, non-profit organization founded to promote the optimization and use of non-animal testing methods. Programs include technical education and outreach to regulators and animal welfare.</i>
Main responsibilities	<i>Interactions with international corporate clients for a large scale (>2000/yr) in vitro testing activities. Oversee cooperative activities with international groups: ECVAM, Zebet, OECD, etc. Publish on individual assays and validation concepts.</i>
Name of employing organisation	<i>Institute for In Vitro Sciences, Inc.</i>
Address of employing organisation (City, Country sufficient)	<i>Gaithersburg, MD, USA</i>
Type of sector	<i>Research Institute</i>
Professional Experience 2	
Occupation or position held	<i>Vice President, Speciality Health and Safety Services</i>
Date (starting)	<i>01.01.1994</i>
Date (finishing)	<i>14.03.1997</i>
Main activities	<i>Directed three departments in areas of In Vitro Toxicology, Biochemical Epidemiology and Laboratory Animal Health Services. Total staff of six Ph.D.s.were active in programs throughout the world.</i>
Main responsibilities	<i>Led the In Vitro Toxicology Division to an international reputation of scientific excellence. Conducted contracting and logistical tasks for the US National Cancer Institute. Developed tests to assure health of laboratory animals.</i>
Name of employing organisation	<i>Microbiological Associates, now BioReliance</i>
Address of employing organisation (City, Country sufficient)	<i>Rockville, MD, USA</i>
Type of sector	<i>Industry (CRO)</i>
Work Experience 3	
Occupation or	<i>Vice President, In Vitro Toxicology</i>



position held	
Date (starting)	<i>30.6.1990</i>
Date (finishing)	<i>19.03.1997</i>
Main activities	<i>Managed a rapidly growing division focusing on the application of in vitro toxicology to problems of acute skin and eye, as well as organ specific, toxicology. Laboratories and offices located both in the U.S. and Europe.</i>
Main responsibilities	<i>Responsible for building a team of scientist with excellent in vitro skills. Oversaw the financial and scientific program of conducted GLP-compliant in vitro assays for major international consumer products and pharmaceutical companies.</i>
Name of employing organisation	<i>Microbiological Associates, now BioReliance</i>
Address of employing organisation (City, Country sufficient)	<i>Rockville, MD, USA</i>
Type of sector	<i>Industry (CRO)</i>
Professional Experience 4	
Occupation or position held	<i>Vice President, Research Program Development</i>
Date (starting)	<i>23.09.1988</i>
Date (finishing)	<i>29.06.1990</i>
Main activities	<i>Directed scientists in multiple research activities to support diverse functions of a large CRO. Activities included toxicology, animal health, and biosafety testing for the biopharmaceutical industry.</i>
Main responsibilities	<i>Responsible for scientific direction and financial performance of R&D department. Helped scientists organize studies to add new and innovative tests to a traditional CRO portfolio. Emphasis placed on molecular techniques.</i>
Name of employing organisation	<i>Microbiological Associates, now BioReliance</i>
Address of employing organisation (City, Country sufficient)	<i>Rockville, MD, USA</i>
Type of sector	<i>Industry (CRO)</i>
Professional Experience 5	
Occupation or position held	<i>Director, Genetic Toxicology Division</i>
Date (starting)	<i>22.09.1988</i>
Date (finishing)	<i>1.1.1988</i>
Main activities	<i>Directed operations of one of the world's leading Genetic Toxicology Groups with staff of four Ph.D.'s and 25 support staff. Supplied GLP-compliant genetox testing to 100's of major international corporations</i>



Main responsibilities	<i>Responsible for hiring of staff, budgeting, and sales for the Division. Determined R&D program and selected assays to move forward to commercial offerings.</i>
Name of employing organisation	<i>Microbiological Associates, now BioReliance</i>
Address of employing organisation (City, Country sufficient)	<i>Rockville, MD, USA</i>
Type of sector	<i>Industry (CRO)</i>
Professional Experience 6	
Occupation or position held	<i>Manager of Operations, Genetic Toxicology</i>
Date (starting)	<i>01.04.1985</i>
Date (finishing)	<i>31.12.1987</i>
Main activities	<i>Oversaw the day-to-day activities of a ~30 person Genetic Toxicology Division. The group conducted assays for bacterial mutation, mammalian cell mutations, chromosomal aberrations, cellular transformation, etc.</i>
Main responsibilities	<i>Providing scheduling priorities for in vitro assays, analyzing testing backlog, recording and analyzing new orders, invoicing and sales projections. Helped Study Directors make final conclusions on results of tests</i>
Name of employing organisation	<i>Microbiological Associates, now BioReliance</i>
Address of employing organisation (City, Country sufficient)	<i>Rockville, MD, USA</i>
Type of sector	<i>Industry (CRO)</i>
Professional Experience 7	
Occupation or position held	<i>Project Director</i>
Date (starting)	<i>01.01.1979</i>
Date (finishing)	<i>31.03.1985</i>
Main activities	<i>Directed numerous US Government R&D contracts in the areas of in vitro carcinogenesis, mutagenesis, tissue culture. Major support lab for the US National Cancer Institute intramural laboratories.</i>
Main responsibilities	<i>Responsible for obtaining biological research contracts (mainly in vitro, tissue culture based) from various agencies in the US Government, hiring individuals to conduct the work, and finally completing the contract on time and within budget.</i>
Name of employing organisation	<i>Microbiological Associates, now BioReliance</i>
Address of employing organisation (City, Country sufficient)	<i>Rockville, MD, USA</i>



Type of sector	Industry (CRO)
----------------	----------------

Professional Experience 8	
Occupation or position held	Assistant Project Director
Date (starting)	15.11.1976
Date (finishing)	31.12.1978
Main activities	Conducting mutagenesis studies and viral transformation studies on multiple National Cancer Institute contracts dealing with in vitro chemical carcinogenesis. Radiation Safety Officer
Main responsibilities	Designing the work program for the tissue culture studies and managing laboratory technicians employed by the contract.
Name of employing organisation	Microbiological Associates, now BioReliance
Address of employing organisation (City, Country sufficient)	Rockville, MD, USA
Type of sector	Industry (CRO)
Professional Experience 9	
Occupation or position held	Research Associate
Date (starting)	01.09.1974
Date (finishing)	01.11.1976
Main activities	Post-doctoral studies on in vitro chemical carcinogenesis with human cells in laboratories of Drs. Veronica Maher and Justin McCormick. Designed and conducted mutagenesis assays in human fibroblasts.
Main responsibilities	Ensuring that the numerous, excessively large, in vitro human cell assays were well planned and competently executed. Oversaw scheduling and scientific activities of laboratory technicians.
Name of employing organisation	Michigan Cancer Foundation
Address of employing organisation (City, Country sufficient)	Detroit, MI, USA
Type of sector	Research Institute
Professional Experience 10	
Occupation or position held	High School Teacher
Date (starting)	01.09.1970
Date (finishing)	05.06.1971
Main activities	Teaching high school (grades 9-12) students mathematics (Grade 9), general science (Grade 10-12, and physics (Grade 12). Also assistant coach for both cross country running and track and field.



Main responsibilities	<i>Responsibility for designing lesson plans and teaching the curriculum acceptable to the State of Ohio Board of Secondary Education.</i>
Name of employing organisation	<i>free text</i>
Address of employing organisation (City, Country sufficient)	<i>Max 100 characters including spaces</i>
Type of sector	<i>Specify (e.g. Academia, Industry, Governmental Body, Public institution, Civil Society Organisation etc.)</i>

4. Educational Background

Educational qualification 1 (most recent)	
Description of qualification achieved (e.g. Bachelor of science in tissue engineering)	<i>Ph.D. in Microbiology</i>
Principal subject (e.g. Animal Physiology)	<i>Bacterial genetics, virology</i>
Other subjects	<i>Immunology</i>
Date (starting)	<i>15.09.1971</i>
Date (finishing)	<i>01.06.1975</i>
Name of organisation (incl. city and country) awarding degree	<i>Rutgers-The State University, New Brunswick, NJ, USA</i>
Title of degree awarded	<i>Ph.D. in Microbiology</i>
Educational qualification 2	
Description of qualification achieved (e.g. Bachelor of science in tissue engineering)	<i>Master of Science in Biology</i>
Principal subject (e.g. Animal Physiology)	<i>Microbiology</i>
Other subjects	<i>Bacterial Physiology, Virology</i>
Date (starting)	<i>05.09.1969</i>
Date (finishing)	<i>08.06.1971</i>
Name of organisation (incl. city and country) awarding degree	<i>Ohio University, Athens, OH, USA</i>
Title of degree awarded	<i>MSc</i>



Educational qualification 3

Description of qualification achieved (e.g. Bachelor of science in tissue engineering)	<i>Bachelor of Science</i>
Principal subject (e.g. Animal Physiology)	<i>Genetics</i>
Other subjects	<i>Physics, Chemistry, Zoology, Engineering</i>
Date (starting)	<i>09.09.1964</i>
Date (finishing)	<i>08.06.1968</i>
Name of organisation (incl. city and country) awarding degree	<i>Purdue University, W. Lafayette, IN, USA</i>
Title of degree awarded	<i>BSc</i>

5. Fellowships, Awards, Membership in Learned Societies, Editorial Boards and Advisory Bodies

5.1 Fellowships

Fellowship I	
Title of fellowship	<i>George Williams Hooper</i>
Description of fellowship (type, maximal duration, prestige)	<i>Supported one summer of independent research at Ohio University</i>
Date (starting)	<i>1.06.1970</i>
Date (finishing)	<i>15.09.1970</i>
Funding/awarding organisation	<i>George Williams Hooper Foundation</i>
Address (city + country sufficient)	<i>San Francisco, CA, USA</i>

5.2 Awards

Award I	
Title of award	<i>William and Eleanor Cave Award</i>
Description of award (type, prestige etc.)	<i>Presented for outstanding achievements in the development, validation, and advancement of humane alternatives for product testing and the promotion of compassion in the biomedical sciences.</i>
Date	<i>23.10.2008</i>
Awarding organisation	<i>Alternative Research and Development Fund</i>
Address (city + country sufficient)	<i>Philadelphia, PA, USA</i>



Award II

Title of award	<i>The Russell and Burch Award</i>
Description of award (type, prestige etc.)	<i>Given for the Advancement of Replacement, Reduction, and Refinement of Animals in Research.</i>
Date	<i>28.09.2007</i>
Awarding organisation	<i>The Humane Society of the United States</i>
Address (city + country sufficient)	<i>Washington, DC, USA</i>

Award III

Title of award	<i>The Björn Ekwall Memorial Award</i>
Description of award (type, prestige etc.)	<i>This award is presented annually at the Scandinavian Society for Cell Toxicology meeting. It was given to Dr. Curren "in recognition of his outstanding contribution to the field of in vitro toxicology, particularly promoting the development, optimization, validation and acceptance of alternative (non-animal) testing and research methods".</i>
Date	<i>25.08.2007</i>
Awarding organisation	<i>The Björn Ekwall Memorial Foundation</i>
Address (city + country sufficient)	<i>Täby, Sweden</i>

5.3 Membership in learned societies & professional associations & editorial boards

Society / Association / Editorial Board I

Society / Association	<i>Society of Toxicology</i>
Description of society's / association's activities	<i>The Society of Toxicology (SOT) is a professional and scholarly organization of scientists from academic institutions, government, and industry representing the great variety of scientists who practice toxicology in the U.S. and abroad. SOT is committed to creating a safer and healthier world by advancing the science of toxicology. The Society promotes the acquisition and utilization of knowledge in toxicology, aids in the protection of public health, and facilitates disciplines.</i>
Membership from ...	<i>01.01.1993</i>
...to (if currently member, please state 'current')	<i>Current</i>
Address (city + country sufficient)	<i>Reston, VA, USA</i>



Society / Association II

Society / Association	<i>Environmental Mutagen Society</i>
Description of society's / association's activities	<i>The EMS mission is (1) to foster scientific research and education on the causes and mechanistic bases of DNA damage and repair, mutagenesis, heritable effects, epigenetic alterations in genome function, and their relevance to disease, and (2) to promote the application and communication of this knowledge to genetic toxicology testing, risk assessment, and regulatory policy-making to protect human health and the environment.</i>
Membership from ...	<i>01.01.2005</i>
...to (if currently member, please state 'current')	<i>Current</i>
Address (city + country sufficient)	<i>Reston, VA, USA</i>

Society / Association III

Society / Association	<i>Scandinavian Society for Cell Toxicology</i>
Description of society's / association's activities	<i>The principle aim of the Scandinavian Society is to further promote the development of cell toxicology. This refers to basic scientific research as well as to applied aspects, e. g. development of in vitro tests with isolated and/or cultured cells, models to predict in vivo toxicity and integrated testing strategies.</i>
Membership from ...	<i>01.01.2007</i>
...to (if currently member, please state 'current')	<i>Current</i>
Address (city + country sufficient)	<i>Stockholm (?), Sweden</i>

Society / Association IV

Society / Association	<i>American Association for the Advancement of Science</i>
Description of society's / association's activities	<i>AAAS is an international non-profit organization dedicated to advancing science around the world by serving as an educator, leader, spokesperson and professional association. In addition to organizing membership activities, AAAS publishes the journal Science, as well as many scientific newsletters, books and reports, and spearheads programs that raise the bar of understanding for science worldwide.</i>
Membership from ...	<i>01.01.1998</i>
...to (if currently member, please state 'current')	<i>Current</i>
Address (city + country sufficient)	<i>Washington, DC, USA</i>



5.4 Membership in advisory bodies / committees

Advisory body / Committee I	
Name of advisory body	<i>Science Advisory Panel – International Foundation For Ethical Research</i>
Description of the roles and responsibilities of the advisory body	<i>The SAP reviews proposals for the selection and funding of IFER's Graduate Fellowship Program. They also agree to mentor certain graduate students to assure that the funding IFER allocates to these projects is properly spent on resources that will make a difference in finding scientifically valid alternatives to the use of animals in research, product testing, and education.</i>
Membership from ...	<i>01.01.2000</i>
...to (if currently member, please state 'current')	<i>Current]</i>
Address (city + country sufficient)	<i>Chicago, IL, USA</i>

Advisory body / Committee II	
Name of advisory body	<i>Science Advisory Panel – A-Cute-Tox Program</i>
Description of the roles and responsibilities of the advisory body	<i>Review and comment on the current studies and future research direction of this EU program attempting to develop in vitro assays to replace animals in acute systemic toxicity studies</i>
Membership from ...	<i>06.01.2006</i>
...to (if currently member, please state 'current')	<i>Current]</i>
Address (city + country sufficient)	<i>Stockholm, SE</i>



Advisory body / Committee III

Name of advisory body	<i>Science Advisory Panel – Personal Care Product Council</i>
Description of the roles and responsibilities of the advisory body	<i>Advises the Council Board of Directors on impending technical issues of concern; Reviews program priorities of other technical committees and task forces and audits their programs; Open to one representative from each active and associate member company with the exception of Council members who are in the media or advertising agencies.</i>
Membership from ...	<i>05..15.2009</i>
...to (if currently member, please state 'current')	<i>Current</i>
Address (city + country sufficient)	<i>Washington, DC, USA</i>



6. Publications

Nr.	Citation
1	Aardema, M, Barnett, B, Khambatta, Z, Reisinger, K., Ouedraogo-Arras. G, Faquet, B, Ginetet, A-C, Mun, G, Dahl, EL, Hewitt, N, Corvi, R and Curren, R. (2010) International Prevalidation Studies of the EpiDerm™ 3D Human Reconstructed Skin Micronucleus (RSMN) Assay: Transferability and Reproducibility, Mutation Research 701 (2010) 123–131.
2	Hartung, T, Bruner, L, Curren, R, Eskes, C, Goldberg, A, McNamee, P, Scott, L, and Zuang, V. (2010) First alternative method validated by a retrospective weight-of-evidence approach to replace the Draize eye test for the identification of non-irritant substances for a defined applicability domain, ALTEX 27:43-51.
3	Curren, R. (2009). An investment in the three Rs can be very profitable, ATLA 37 Suppl. 2: 35-38.
4	Curren, R. (2009). Animal use in the chemical and product manufacturing sectors – can the downtrend continue? ATLA 37:623-629.
5	Curren RD, Mun GC, Gibson DP, and Aardema MJ. (2006) Development of a method for assessing micronucleus induction in a 3D human skin model (EpiDerm™). Mutation Research 607:192-204
6	Curren RD, Southee JA, Spielmann H, Liebsch M, Fentem JH, and Balls M. (1995) The role of prevalidation in the development validation and acceptance of alternative methods. ATLA, 23: 211-217.
7	Mun GC, Aardema MJ, Hu T, Barnett B, Kaluzhny Y, Klausner M, Karetsky V, Dahl EL, Curren RD. (2009). Further development of the EpiDerm™ 3D reconstructed human skin micronucleus (RSMN) assay, Mutation Research 673:92–99
8	Bruner LH, Carr GJ, Chamberlain M, and Curren RD. (1996) Validation of alternative methods for toxicology testing. Toxicology In Vitro 10: 479-501
9	Harbell JW and Curren RD. In vitro methods for the prediction of ocular and dermal toxicity. In, Handbook of Toxicology, 2nd Ed. 2001
10	Curren RD and Harbell JW. In Vitro Alternatives for Ocular Irritation. (1998) Environ. Health Perspect. 106 (2): 485-492.
11	Curren RD and Harbell JW. (2002) Ocular safety: a silent (in vitro) success story. Altern Lab Anim 30 Suppl 2:69-74
12	Bruner LH, Carr GJ, Harbell JW and Curren RD. (2002) An investigation of new toxicity test method performance in validation studies: 1. Toxicity test methods that have predictive capacity no greater than chance. Human and Experimental Toxicology 21:305-312
13	Bruner LH, Carr GJ, Harbell JW and Curren RD. (2002) An investigation of new toxicity test method performance in validation studies: 2. Comparison of three measures of toxicity test performance. Human and Experimental Toxicology 21:313-323
14	Bruner LH, Carr GJ, Harbell JW, and Curren RD. (2002) An investigation of new toxicity test method performance in validation studies: 3. Sensitivity and specificity are not independent of prevalence or distribution of toxicity. Human and Experimental Toxicology 21:325-334



15	<i>Becker RA, Borgert CJ, Webb S, Ansell J, Amundson S, Portier CJ, Goldberg, A, Bruner, LH, Rowan, A, Curren, RD, Stott, WT. (2006). Report of an IS RTP Workshop: Progress and barriers to incorporating alternative toxicological methods in the U.S. Regul Toxicol Pharmacol 46(1):18-22</i>
16	<i>Eskes C, Bessou S, Burner L, Curren R, Harbell J, Jones P, Kreiling R, Liebsch M, McNamee P, Pape W, Prinsen MK, Seidle T, Vanparys P, Worth A, Zuang V. (2005) Eye irritation. Altern Lab Anim. 33 Suppl 1:47-81</i>
17	<i>Zuang V, Balls M, Botham PA, Coquette A, Corsini E, Curren RD, et al. (2002). Follow-up to the ECVAM prevalidation study on in vitro tests for acute skin irritation. The European Centre for the Validation of Alternative Methods Skin Irritation Task Force Report 2. Altern Lab Anim 30(1):109-129</i>
18	<i>Curren, R. D., and Southee, J. A. Prevalidation: successes justify the concept. In Progress in the Reduction, Refinement and Replacement of Animal Experimentation (M. Balls, A.-M. van Zeller and M. E. Halder, eds.), pp. 359-364. Elsevier Science B.V., The Netherlands. 2000.</i>
19	<i>Curren, RD, Bruner, LH, Goldberg, AH and Walum, E. (1998). Validation and Acute Toxicity Testing. Environ. Health Perspect. 106 (2): 419-426.</i>
20	<i>Fentem, JH, Archer, GEB, Balls, M, Botham, PA, Curren, RD, Earl, LK, Esdaile, DJ, Holzutter, H-G, and Liebsch, M.(1998). The ECVAM International Validation Study on In Vitro Tests for Skin Corrosivity. 2. Results and Evaluation by the Management Team, Toxicology In Vitro. 12:471-482</i>
21	<i>Harbell. JW., Curren, RD. (1998). The bovine corneal opacity and permeability assay: Observation on assay performance. In Vitro & Molecular Toxicology, 11, (4): 337-341</i>
22	<i>Curren, R.D., Harbell, J.W., Raabe, H.A, Sussman RG, and Kimmel TA (1997). The utility of a two-test in vitro battery to assess the ocular irritancy of drug intermediates. In: Animal Alternatives Welfare and Ethics: 583-589, Elsevier, Amsterdam.</i>
23	<i>Curren, R.D., Harbell, J.W., and Southee, J.A. (1997) Current approaches to the in vitro prediction of ocular irritation. Comments in Toxicology. 6: 71-85.</i>
24	<i>Curren, R.D., Sina, J.F., Feder, P., Kruszewski, F.H., Osborne, R., and Regnier, J.-F.(1997) IRAG WORKING GROUP 5, Other Assays. Fd. Chem. Toxicol. 35: 127-158.</i>